Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925274 · ClinicalTrials.gov registry record · Phase 2
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT01925274 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 19 participants.
The verdict
NCT01925274, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of cetuximab plus Irinotecan. A Japanese Lead in Cohort will assess the safety of the combination of PF-05212384 + irinotecan in patients enrolled at Japanese sites.
Interventions
- DRUG Cetuximab
- DRUG Irinotecan
- DRUG irinotecan
- DRUG PF-05212384
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-11-15 |
| Est. Completion | 2016-04-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925274
The ClinicalTrials.gov registry entry for NCT01925274 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cetuximab is the first listed.
NCT01925274 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01925274 about?
NCT01925274 is a clinical study titled "A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer". This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of cetuximab plus Irinotecan. A Japanese Lead in Cohort will assess the safet...
What is the current status of trial NCT01925274?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2013-11-15. Estimated completion is 2016-04-06.
What interventions are being tested in trial NCT01925274?
The interventions under investigation include: Cetuximab (DRUG), Irinotecan (DRUG), irinotecan (DRUG), PF-05212384 (DRUG).
Who is sponsoring clinical trial NCT01925274?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.